New combo therapy aims to outsmart 'Cold' rectal tumors
NCT ID NCT07026422
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II trial tests whether adding a dual immunotherapy drug (iparomlimab/tuvonralimab) to standard chemoradiotherapy can improve outcomes for patients with locally advanced rectal cancer that has a specific genetic profile (pMMR/MSS), which usually does not respond to immunotherapy alone. The study plans to enroll 54 participants and will measure the rate of complete tumor disappearance. The goal is to see if this combination can turn 'immune-cold' tumors into 'hot' ones that respond better to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- iparomlimab/tuvonralimab (a dual immunotherapy drug) combined with chemoradiotherapy
- What this could lead to
- If successful, this could offer a new treatment option for patients with a common type of rectal cancer that typically does not respond well to immunotherapy alone.
- What could go wrong
- This is an early, small Phase II trial with only 54 participants, so results may not apply broadly. The combination therapy may cause side effects from both immunotherapy and chemoradiotherapy, and it is not yet known if it will improve long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PMMR/MSS LOCALLY ADVANCED RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shandong Cancer Hospital and Institute
RECRUITINGJinan, Shandong, 250000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diet and vitamin c supercharge rectal cancer treatment?
- AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
- A new radiation combo may spare the rectum in early cancer
- Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
- Metabolic MRI may reveal hidden cancer responses and spare patients from surgery
- Can a beetroot drink spot dangerous surgical leaks before they turn deadly?